JP2022519595A5 - - Google Patents
Info
- Publication number
- JP2022519595A5 JP2022519595A5 JP2021545400A JP2021545400A JP2022519595A5 JP 2022519595 A5 JP2022519595 A5 JP 2022519595A5 JP 2021545400 A JP2021545400 A JP 2021545400A JP 2021545400 A JP2021545400 A JP 2021545400A JP 2022519595 A5 JP2022519595 A5 JP 2022519595A5
- Authority
- JP
- Japan
- Prior art keywords
- targeting
- zc3h12a
- socs1
- molecule
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098698A JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800999P | 2019-02-04 | 2019-02-04 | |
| US62/800,999 | 2019-02-04 | ||
| US201962818677P | 2019-03-14 | 2019-03-14 | |
| US62/818,677 | 2019-03-14 | ||
| PCT/US2020/016623 WO2020163365A2 (en) | 2019-02-04 | 2020-02-04 | Combination gene targets for improved immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Division JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519595A JP2022519595A (ja) | 2022-03-24 |
| JP2022519595A5 true JP2022519595A5 (enExample) | 2023-02-10 |
Family
ID=71947815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545400A Pending JP2022519595A (ja) | 2019-02-04 | 2020-02-04 | 免疫療法の改善のための遺伝子標的の組み合わせ |
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200347386A1 (enExample) |
| EP (1) | EP3920942A4 (enExample) |
| JP (2) | JP2022519595A (enExample) |
| KR (1) | KR20210138587A (enExample) |
| CN (1) | CN113396216A (enExample) |
| AU (1) | AU2020217715A1 (enExample) |
| BR (1) | BR112021015170A2 (enExample) |
| CA (1) | CA3128823A1 (enExample) |
| IL (1) | IL285307A (enExample) |
| MX (1) | MX2021009357A (enExample) |
| SG (1) | SG11202108452WA (enExample) |
| WO (1) | WO2020163365A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN112040986A (zh) | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| CA3192344A1 (en) * | 2020-08-28 | 2022-03-03 | Genentech, Inc. | Crispr/cas9 multiplex knockout of host cell proteins |
| US20240060091A1 (en) * | 2020-12-17 | 2024-02-22 | University of Florida Research Foundation, Incorporation | Method for programmable control of rna transcript levels with autoregulated crispr-cas13d |
| US12171813B2 (en) | 2021-02-05 | 2024-12-24 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| EP4305153A1 (en) | 2021-03-09 | 2024-01-17 | CRISPR Therapeutics AG | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
| WO2023015213A1 (en) * | 2021-08-03 | 2023-02-09 | Spotlight Therapeutics | Ptpn2 specific guide rnas and uses thereof |
| JP2024537991A (ja) | 2021-10-14 | 2024-10-18 | アーセナル バイオサイエンシズ インコーポレイテッド | 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞 |
| WO2023082640A1 (zh) * | 2021-11-10 | 2023-05-19 | 清华大学 | 增强免疫细胞持久性的方法 |
| PE20241474A1 (es) * | 2021-11-23 | 2024-07-17 | Kumquat Biosciences Inc | Compuestos que contienen heteroatomos y usos de estos |
| WO2023131053A1 (zh) * | 2022-01-05 | 2023-07-13 | 苏州系统医学研究所 | 一种t细胞受体及其制备方法和用途 |
| WO2023143515A1 (zh) * | 2022-01-29 | 2023-08-03 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| CN116790667A (zh) * | 2023-07-12 | 2023-09-22 | 中国医科大学 | 巨噬细胞条件性基因敲除小鼠模型的建立及其应用 |
| WO2025054946A1 (zh) * | 2023-09-15 | 2025-03-20 | 毕诺济(上海)生物技术有限公司 | 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用 |
| WO2025082418A1 (zh) * | 2023-10-18 | 2025-04-24 | 苏州沙砾生物科技有限公司 | 一种鉴定靶标的方法及其应用 |
| CN117883382B (zh) * | 2023-11-27 | 2025-02-14 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途 |
| WO2025126049A2 (en) * | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2025223340A1 (zh) * | 2024-04-22 | 2025-10-30 | 苏州沙砾生物科技有限公司 | 一种鉴定靶标的方法及其应用 |
| WO2026064475A1 (en) * | 2024-09-18 | 2026-03-26 | Editas Medicine, Inc. | Crispr cas-related methods and compositions targeting ptpn2 expression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
| JP2008522951A (ja) * | 2004-07-19 | 2008-07-03 | ベイラー・カレツジ・オブ・メデイシン | サイトカインシグナル伝達調節物質の調節および免疫療法のための応用 |
| US20130331294A1 (en) * | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
| JPWO2010098429A1 (ja) * | 2009-02-27 | 2012-09-06 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| CA3051222C (en) * | 2013-06-10 | 2023-01-24 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| CN106459995B (zh) * | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| EP3154555A4 (en) * | 2014-06-10 | 2018-02-28 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| WO2018148378A1 (en) * | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy |
| CN112041433A (zh) * | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| CN116322716A (zh) * | 2020-09-23 | 2023-06-23 | 克里斯珀医疗股份公司 | Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性 |
-
2020
- 2020-02-04 CN CN202080012560.2A patent/CN113396216A/zh active Pending
- 2020-02-04 AU AU2020217715A patent/AU2020217715A1/en active Pending
- 2020-02-04 EP EP20751889.5A patent/EP3920942A4/en active Pending
- 2020-02-04 SG SG11202108452WA patent/SG11202108452WA/en unknown
- 2020-02-04 KR KR1020217028228A patent/KR20210138587A/ko not_active Ceased
- 2020-02-04 BR BR112021015170-2A patent/BR112021015170A2/pt unknown
- 2020-02-04 MX MX2021009357A patent/MX2021009357A/es unknown
- 2020-02-04 WO PCT/US2020/016623 patent/WO2020163365A2/en not_active Ceased
- 2020-02-04 JP JP2021545400A patent/JP2022519595A/ja active Pending
- 2020-02-04 US US16/781,732 patent/US20200347386A1/en active Pending
- 2020-02-04 CA CA3128823A patent/CA3128823A1/en active Pending
-
2021
- 2021-08-02 IL IL285307A patent/IL285307A/en unknown
-
2024
- 2024-06-19 JP JP2024098698A patent/JP2024111155A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519595A5 (enExample) | ||
| JP2021518162A5 (enExample) | ||
| JP2021518160A5 (enExample) | ||
| JP2021518161A5 (enExample) | ||
| Bozza et al. | A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells | |
| Khan et al. | Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors | |
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| Zhang et al. | IFN-γ enhances the efficacy of mesenchymal stromal cell-derived exosomes via miR-21 in myocardial infarction rats | |
| Bernstein et al. | TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts | |
| Soldevilla et al. | 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia | |
| Chak et al. | Downregulation of long non‐coding RNA MEG3 in nasopharyngeal carcinoma | |
| Chen et al. | Circular RNA cia-MAF drives self-renewal and metastasis of liver tumor-initiating cells via transcription factor MAFF | |
| US20200158716A1 (en) | Cell atlas of healthy and diseased barrier tissues | |
| US20250122471A1 (en) | Engineered antigen presenting cells and uses thereof | |
| Ellert-Miklaszewska et al. | Efficient and innocuous delivery of small interfering RNA to microglia using an amphiphilic dendrimer nanovector | |
| Webber et al. | Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair | |
| AU2020214807A1 (en) | Microenvironment sensors to regulate engineered gene expression | |
| JP2019517815A5 (enExample) | ||
| JP2025156332A (ja) | エクスビボ細胞療法用途のための免疫細胞の操作 | |
| Chen et al. | Epigenetics regulates antitumor immunity in melanoma | |
| Economos et al. | Antispacer peptide nucleic acids for sequence-specific CRISPR-Cas9 modulation | |
| Kovaleva et al. | M1 macrophages–unexpected contribution to tumor progression | |
| EP4255501A1 (en) | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy | |
| US20250136936A1 (en) | Nucleic acid modified biological cell with expansion-dependent gene expression | |
| Stathopoulou et al. | Long non-coding RNA SeT and miR-155 regulate the Tnfα gene allelic expression profile |